Dariush Ashrafi, MD
Family Medicine · Richmond, VANPI 1659545614
Payments from drug & device makers
Across 499 payments — averaging $13.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$538
- Pfizer$430
- AstraZeneca$388
- Sanofi-aventis U.S. LLC$292
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$261
- plus $3K from 28 others
What the payments were for
- Travel & lodging$1472%
- Food & beverage$6,57597%
- Education$250%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 215 | $2,152 |
| Novo Nordisk | 41 | $538 |
| Pfizer | 27 | $430 |
| AstraZeneca | 17 | $388 |
| Sanofi-aventis U.S. LLC | 17 | $292 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 18 | $261 |
| Lilly USA, LLC | 16 | $251 |
| GSK | 17 | $242 |
| Novartis | 11 | $199 |
| Amgen | 12 | $181 |
| Biohaven Pharmaceutical Holding Company Ltd. | 9 | $180 |
| Abbott | 8 | $176 |
| Biohaven Pharmaceuticals, Inc. | 8 | $169 |
| Otsuka America Pharmaceutical, Inc. | 8 | $151 |
| Intuitive Surgical | 2 | $147 |
| Merck | 12 | $140 |
| Scilex Pharmaceuticals Inc. | 11 | $118 |
| Bayer | 7 | $107 |
| Boehringer Ingelheim | 6 | $91 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $85 |
| Vanda Pharmaceuticals Inc. | 4 | $77 |
| Johnson & Johnson | 5 | $65 |
| Exact Sciences | 2 | $46 |
| Xeris Pharmaceuticals, Inc. | 2 | $44 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $38 |
| Ardelyx, Inc. | 2 | $31 |
| Valeritas, Inc. | 2 | $29 |
| Bausch Health US, LLC | 1 | $20 |
| Ironwood Pharmaceuticals, Inc | 1 | $19 |
| Dexcom, Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Corium, LLC | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,748 in reported general payments places this provider in the 90th percentile of 2,553 family medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 155 | $185,728 |
| TrulicityDulaglutide | 133 | $152,513 |
| EliquisApixaban | 115 | $116,221 |
| JanumetSitagliptin Phos/Metformin Hcl | 99 | $105,197 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 58 | $59,496 |
| JardianceEmpagliflozin | 63 | $54,572 |
| Nurtec OdtRimegepant Sulfate | 11 | $28,643 |
| FarxigaDapagliflozin Propanediol | 12 | $19,443 |
| JanuviaSitagliptin Phosphate | 21 | $19,396 |
| SynjardyEmpagliflozin/Metformin Hcl | 14 | $19,379 |
| LinzessLinaclotide | 25 | $18,061 |
| EntrestoSacubitril/Valsartan | 14 | $15,856 |
| SymbicortBudesonide/Formoterol Fumarate | 37 | $14,550 |
| XareltoRivaroxaban | 12 | $13,721 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $10,757 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $538 | $185,728155 claims |
| Lilly USA, LLCTrulicity | $251 | $152,513133 claims |
| PfizerEliquis, Nurtec Odt, Premarin | $430 | $148,391137 claims |
| MerckJanumet, Januvia | $140 | $124,592120 claims |
| Boehringer IngelheimJardiance, Synjardy, Combivent Respimat, Spiriva Respimat | $91 | $91,134103 claims |
| GSKTrelegy Ellipta | $242 | $59,49658 claims |
| AstraZenecaFarxiga, Symbicort | $388 | $33,99349 claims |
| AbbVieLinzess | $2,152 | $18,06125 claims |
| NovartisEntresto | $199 | $15,85614 claims |
| Johnson & JohnsonXarelto | $65 | $13,72112 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $261 | $7,31111 claims |
| Astellas Pharma US IncMyrbetriq | $17 | $4,31111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,553 family medicine providers in Virginia.
Other family medicine in Richmond
- Paul StairsRichmond$105K
- Edwin RobinsonRichmond$83K
- Banks TurnerRichmond$74K
- James FosterRichmond$27K
- George MaughanRichmond$21K
- Aaron HartmanMidlothian$17.4M
- John ScottGlen Allen$16.7M
- Banu MyneniPortsmouth$12.8M
- Patricia HouserWinchester$3.5M
- Stephan JannachDanville$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.